Innoviva, Inc. (INVA)
23.00
+0.46
(+2.04%)
USD |
NASDAQ |
Jun 10, 16:00
22.84
-0.16
(-0.70%)
After-Hours: 07:28
Innoviva Enterprise Value : 1.417B for June 10, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| June 10, 2026 | 1.417B |
| June 09, 2026 | 1.383B |
| June 08, 2026 | 1.368B |
| June 05, 2026 | 1.382B |
| June 04, 2026 | 1.355B |
| June 03, 2026 | 1.321B |
| June 02, 2026 | 1.295B |
| June 01, 2026 | 1.307B |
| May 29, 2026 | 1.300B |
| May 28, 2026 | 1.335B |
| May 27, 2026 | 1.353B |
| May 26, 2026 | 1.393B |
| May 22, 2026 | 1.377B |
| May 21, 2026 | 1.358B |
| May 20, 2026 | 1.361B |
| May 19, 2026 | 1.323B |
| May 18, 2026 | 1.329B |
| May 15, 2026 | 1.341B |
| May 14, 2026 | 1.407B |
| May 13, 2026 | 1.427B |
| May 12, 2026 | 1.398B |
| May 11, 2026 | 1.382B |
| May 08, 2026 | 1.409B |
| May 07, 2026 | 1.402B |
| May 06, 2026 | 1.382B |
| Date | Value |
|---|---|
| May 05, 2026 | 1.391B |
| May 04, 2026 | 1.416B |
| May 01, 2026 | 1.425B |
| April 30, 2026 | 1.416B |
| April 29, 2026 | 1.421B |
| April 28, 2026 | 1.468B |
| April 27, 2026 | 1.444B |
| April 24, 2026 | 1.459B |
| April 23, 2026 | 1.452B |
| April 22, 2026 | 1.454B |
| April 21, 2026 | 1.462B |
| April 20, 2026 | 1.485B |
| April 17, 2026 | 1.509B |
| April 16, 2026 | 1.461B |
| April 15, 2026 | 1.485B |
| April 14, 2026 | 1.505B |
| April 13, 2026 | 1.489B |
| April 10, 2026 | 1.473B |
| April 09, 2026 | 1.506B |
| April 08, 2026 | 1.463B |
| April 07, 2026 | 1.438B |
| April 06, 2026 | 1.419B |
| April 02, 2026 | 1.416B |
| April 01, 2026 | 1.447B |
| March 31, 2026 | 1.439B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ANI Pharmaceuticals, Inc. | 2.161B |
| Corcept Therapeutics, Inc. | 8.056B |
| Assertio Holdings, Inc. | 120.08M |
| Veru, Inc. | 19.42M |
| Johnson & Johnson | 606.88B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 186.60M |
| Revenue (Quarterly) | 101.45M |
| Total Expenses (Quarterly) | -85.14M |
| EPS Diluted (Quarterly) | 2.216 |
| Gross Profit Margin (Quarterly) | 74.75% |
| Earnings Yield | 26.15% |
| Operating Earnings Yield | 8.22% |
| Normalized Earnings Yield | 10.69 |